Source - SMW
Motif Bio intends to raise about £19.4m via a conditional placing with new and existing investors to fund the further development of iclaprim, its novel antibiotic candidate.

The placing was being conducted via an accelerated bookbuild exercise. 

Net proceeds would be used to complete the REVIVE-2 study, to file an NDA and a MAA for iclaprim in ABSSSI, and for general corporate purposes.